ZGNX

Zogenix

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$525.2M

Burn Rate (Qtr)

-$60.1M

Company Profile

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

FINTEPLA (ZX008)

Dravet syndrome

Quarterly Sales (Approved)

February 26, 2021 (Est)

ZX008

Lennox-Gastaut syndrome

sNDA Submission (Meeting with FDA)

2021

MT1621

Thymidine Kinase 2 (TK2) Deficiency

Phase 2 (Open Label)

TBD

ZX008

Multiple Rare Epilepsies

Phase 2

TBD

Recent Posts

See what the community is saying - click to see full post

ZGNX - Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results

ZGNX - Zogenix Announces Date Change for Third Quarter 2020 Financial Results and Conference Call and Webcast

ZGNX - Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on Novembe

ZGNX - Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patie

ZGNX - Presents New Data for FINTEPLA® in Dravet Syndrome at CNS 2020

ZGNX - Zogenix Announces Positive Top-Line Results from its Third Pivotal Phase 3 Clinical Trial (Study 3) of

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon